WINTON GROUP Ltd Has $6.69 Million Holdings in BioMarin Pharmaceutical Inc. $BMRN

WINTON GROUP Ltd increased its position in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) by 2,835.0% in the third quarter, Holdings Channel.com reports. The institutional investor owned 123,474 shares of the biotechnology company’s stock after buying an additional 119,267 shares during the period. WINTON GROUP Ltd’s holdings in BioMarin Pharmaceutical were worth $6,687,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also bought and sold shares of BMRN. Quent Capital LLC bought a new stake in BioMarin Pharmaceutical during the third quarter valued at $28,000. Smartleaf Asset Management LLC lifted its stake in shares of BioMarin Pharmaceutical by 92.5% in the 3rd quarter. Smartleaf Asset Management LLC now owns 749 shares of the biotechnology company’s stock valued at $40,000 after purchasing an additional 360 shares during the period. Parallel Advisors LLC lifted its stake in shares of BioMarin Pharmaceutical by 62.2% in the 3rd quarter. Parallel Advisors LLC now owns 769 shares of the biotechnology company’s stock valued at $42,000 after purchasing an additional 295 shares during the period. Employees Retirement System of Texas bought a new stake in shares of BioMarin Pharmaceutical during the 2nd quarter valued at about $58,000. Finally, Jones Financial Companies Lllp boosted its position in shares of BioMarin Pharmaceutical by 88.1% during the 3rd quarter. Jones Financial Companies Lllp now owns 1,401 shares of the biotechnology company’s stock valued at $75,000 after purchasing an additional 656 shares in the last quarter. Institutional investors and hedge funds own 98.71% of the company’s stock.

BioMarin Pharmaceutical Stock Up 0.9%

Shares of NASDAQ:BMRN opened at $61.12 on Monday. The company has a debt-to-equity ratio of 0.10, a quick ratio of 3.50 and a current ratio of 5.21. BioMarin Pharmaceutical Inc. has a 52-week low of $50.76 and a 52-week high of $73.51. The business’s 50 day simple moving average is $58.92 and its two-hundred day simple moving average is $56.25. The firm has a market cap of $11.75 billion, a P/E ratio of 34.34, a PEG ratio of 0.53 and a beta of 0.25.

Insider Buying and Selling at BioMarin Pharmaceutical

In related news, EVP Gregory R. Friberg sold 6,326 shares of the stock in a transaction on Thursday, February 26th. The stock was sold at an average price of $60.38, for a total value of $381,963.88. Following the transaction, the executive vice president directly owned 37,578 shares in the company, valued at $2,268,959.64. This trade represents a 14.41% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 0.85% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

A number of brokerages have weighed in on BMRN. Leerink Partners downgraded BioMarin Pharmaceutical from an “outperform” rating to a “market perform” rating and lowered their target price for the stock from $82.00 to $60.00 in a report on Wednesday, December 3rd. Truist Financial raised their price objective on shares of BioMarin Pharmaceutical from $80.00 to $100.00 and gave the stock a “buy” rating in a research report on Tuesday, December 23rd. Guggenheim lowered their price objective on shares of BioMarin Pharmaceutical from $106.00 to $86.00 and set a “buy” rating for the company in a research note on Wednesday, February 25th. Wells Fargo & Company boosted their target price on shares of BioMarin Pharmaceutical from $70.00 to $75.00 and gave the company an “overweight” rating in a research report on Wednesday, February 18th. Finally, Barclays increased their target price on shares of BioMarin Pharmaceutical from $80.00 to $105.00 and gave the stock an “overweight” rating in a research note on Tuesday, March 3rd. Fifteen analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $89.64.

BioMarin Pharmaceutical Profile

BioMarin Pharmaceutical Inc is a biopharmaceutical company specializing in the development and commercialization of therapies for rare genetic and metabolic diseases. The company focuses on addressing unmet medical needs by leveraging enzyme replacement therapy, small molecule pharmacological chaperones and gene therapy technologies. Headquartered in Novato, California, BioMarin operates research and development facilities in the United States and Europe.

The company’s commercial portfolio includes several approved therapies targeting inherited disorders.